Carl Dambkowski Sells 18,700 Shares of Apogee Therapeutics (NASDAQ:APGE) Stock

Apogee Therapeutics Inc. (NASDAQ:APGE) insider Carl Dambkowski sold 18,700 shares of the firm’s stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $77.84, for a total transaction of $1,455,608.00. Following the completion of the sale, the insider owned 212,523 shares of the company’s stock, valued at $16,542,790.32. The trade was a 8.09% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.

Carl Dambkowski also recently made the following trade(s):

• On Thursday, December 4th, Carl Dambkowski sold 10,900 shares of Apogee Therapeutics stock. The shares were sold at an average price of $75.00, for a total transaction of $817,500.00.
• On Wednesday, November 5th, Carl Dambkowski sold 10,785 shares of Apogee Therapeutics stock. The stock was sold at an average price of $55.07, for a total transaction of $593,929.95.

Apogee Therapeutics Trading Up 0.7%

Shares of NASDAQ APGE opened at $77.99 on Friday. The firm has a market capitalization of $5.33 billion, a PE ratio of -17.81 and a beta of 1.41. The firm’s 50-day moving average is $70.89 and its 200-day moving average is $51.91. Apogee Therapeutics Inc. has a 1 year low of $26.20 and a 1 year high of $80.99.

Apogee Therapeutics (NASDAQ:APGE) last posted its earnings results on Monday, November 10th. The company reported ($1.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.14) by $0.03. As a group, equities research analysts anticipate that Apogee Therapeutics Inc. will post -3.09 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Apogee Therapeutics

A number of large investors have recently made changes to their positions in the company. Wellington Management Group LLP grew its stake in shares of Apogee Therapeutics by 24.1% in the third quarter. Wellington Management Group LLP now owns 4,723,701 shares of the company’s stock valued at $187,673,000 after acquiring an additional 917,991 shares in the last quarter. UBS Group AG boosted its holdings in Apogee Therapeutics by 646.1% in the 3rd quarter. UBS Group AG now owns 799,465 shares of the company’s stock valued at $31,763,000 after purchasing an additional 692,308 shares during the period. Adage Capital Partners GP L.L.C. grew its position in shares of Apogee Therapeutics by 77.5% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 1,290,464 shares of the company’s stock worth $56,045,000 after purchasing an additional 563,464 shares in the last quarter. Paradigm Biocapital Advisors LP increased its holdings in shares of Apogee Therapeutics by 58.7% during the third quarter. Paradigm Biocapital Advisors LP now owns 1,521,757 shares of the company’s stock worth $60,459,000 after purchasing an additional 563,127 shares during the period. Finally, Vestal Point Capital LP acquired a new stake in shares of Apogee Therapeutics in the third quarter valued at approximately $16,885,000. Institutional investors own 79.04% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. Wall Street Zen downgraded Apogee Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, December 6th. Deutsche Bank Aktiengesellschaft assumed coverage on Apogee Therapeutics in a research note on Tuesday, December 9th. They issued a “buy” rating and a $103.00 target price on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Apogee Therapeutics in a research note on Wednesday, October 8th. UBS Group raised shares of Apogee Therapeutics to a “strong-buy” rating in a research report on Wednesday. Finally, Stephens assumed coverage on shares of Apogee Therapeutics in a report on Tuesday, December 16th. They set an “overweight” rating and a $95.00 target price for the company. Three investment analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $104.27.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.

The company’s lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.